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Functional imaging may be useful for both the early diagnosis as well as preclinical detection of
neurodegenerative disease. Additionally, while structural imaging has traditionally been regarded as a tool to
exclude alternate diagnoses, recent advances in magnetic resonance show promise for greater diagnostic
specificity. The role of MR and radionuclide imaging in early diagnosis and preclinical detection of dementia and
parkinsonism are reviewed here.
Introduction
Neurodegenerative disorders, of which Alzheimer’s (AD)
and Parkinson’s (PD) diseases are the most common,
take an enormous toll on affected patients and their
families. For example, a recent analysis indicates that
dementia and PD combined affect more than 7.5 million
Europeans, at an estimated annual cost of €120 billion
[1] and incalculable suffering. While symptomatic thera-
pies are currently available, they are at best imperfect
(PD), at worst provide only modest benefit (dementia)
and they do not have any convincing impact on the
inexorable progression of the underlying disorder.
Advances in basic neuroscience make it increasingly
likely that disease modifying therapies will be developed
but these are likely to have maximal impact if they are
introduced early in the course of the illness. Early dis-
ease detection would permit the provision of such thera-
pies to those most likely to benefit from them, at the
time that they are most likely to be effective. Early diag-
nosis permits the identification of people appropriate for
inclusion in clinical trials of novel therapies and the
exclusion of those who are not. Finally, early diagnosis
allows better prognostication and appropriate resource
utilization.
A variety of neuroimaging techniques may be useful
for the early diagnosis of neurodegenerative disorders,
but one should first consider the goal. Early diagnosis
may refer to the timely correct differentiation of a
specific disease entity from other conditions that may
mimic it in early stages, or it may refer to the early
detection of central nervous system dysfunction, prior to
the emergence of clinical symptoms. The latter applica-
tion is more likely to be of interest in populations at
increased risk of disease, and could be useful for identi-
fication of subjects to participate in trials of neuropro-
tective agents, or ultimately to try and halt disease
progression once effective disease-modifying interven-
tions have been identified.
Early differential diagnosis
Parkinsonism
In the case of PD, the two major diagnostic considera-
tions are either conditions that produce tremor but are
not associated with dopamine deficiency (i.e. essential
tremor or dystonic tremor) or other conditions that
result in an akinetic-rigid syndrome, such as multiple
system atrophy (MSA) or progressive supranuclear palsy
(PSP). Imaging with radiotracers that assess presynaptic
dopamine function such as single photon emission com-
puted tomography (SPECT) using the dopamine trans-
porter (DAT) ligand [123I]FP-CIT (DaTscan) will reliably
differentiate between PD and ET [2]. Several studies in
which imaging was conducted as an outcome measure
in patients thought to have early PD found that dopa-
mine function (assessed using DAT SPECT or [18F]F-
dopa PET) was preserved in approximately 15% of
patients [3,4]. This phenomenon, which has become
known as Scans Without Evidence of Dopamine Defi-
ciency (SWEDD) is now thought to mostly correlate
with dystonic tremor [5]. Such subjects do not show
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evidence of disease progression on serial DAT studies
[6], are not dependent upon dopaminergic medication
[7] and careful examination reveals the clinical features
to be distinct from PD [8,9].
The more challenging diagnostic consideration is the
separation of PD from other akinetic-rigid syndromes.
While PD shows a characteristic pattern of impaired
dopaminergic function that is asymmetric and affects
the posterior more than the anterior striatum [10], this
pattern may also be seen in MSA [11] and is therefore
insufficient on its own to reliably differentiate between
the two conditions. However, MSA is typically asso-
ciated with loss of dopamine receptors, which are pre-
served in PD. Thus the combination of pre- and post-
synaptic abnormalities of dopamine transmission may
help differentiate PD from the Parkinson-plus syn-
dromes [11,12]. Two other radiotracer approaches are
worth considering for the differentiation of PD from
other akinetic-rigid syndromes. PD is associated with a
characteristic pattern of increased glucose metabolism
in basal ganglia and cerebellum with concurrent reduc-
tions in multiple cortical regions, the so-called PD
Related Pattern (PDRP)[13]. This pattern is not seen in
MSA, PSP or other akinetic-rigid conditions such as
corticobasal syndrome and the pattern of glucose meta-
bolism can be used for diagnostic classification with a
high degree of specificity [14,15]. Finally, PD is fre-
quently associated with autonomic dysfunction reflecting
degeneration of sympathetic ganglia, whereas in MSA,
the degeneration is predominantly central. Thus cardiac
sympathetic imaging using [123I]MIBG (SPECT), or
[11C]m-hydroxyephedrine or [18F]fluorodopamine (PET)
is typically abnormal in PD, but preserved MSA and
PSP [16-18], although the differentiation may not be
entirely reliable [19].
Traditional MRI changes of MSA (increased iron
deposition in globus pallidus, rim of putaminal hyperin-
tensity, “hot cross bun sign”)[20] and PSP ("humming-
bird sign”)[21] may not be entirely reliable, particularly
in early disease. However, diffusion MRI may allow diag-
nostic differentiation [22-24], and PSP may be identified
by detailed measurements of the midbrain and superior
cerebellar peduncles [25]. Multimodal MR techniques
assessing diffusivity (microstructural damage), fractional
anisotropy (white matter tract integrity) and iron appear
to separate PD from controls with a high degree of sen-
sitivity and specificity [26] but have not yet been routi-
nely applied to differential diagnosis.
Dementia
MRI may clearly be of help in differentiating between
Alzheimer disease (AD) and multi-infarct dementia.
Amongst the other degenerative causes of dementia,
dementia with Lewy bodies (DLB) and frontotemporal
dementias are the most important. Structural MRI
shows atrophy of the hippocampus and entorhinal cor-
tex in AD [27], as well as involvement of the lateral par-
ietal, posterior superior temporal and medial posterior
cingulate cortices. This is in contrast to FTD, where
atrophy is more prominent in frontal or temporal poles.
However, while the pattern of atrophy may help differ-
entiate some variants of FTD, there is considerable over-
lap between Pick complex and AD [28]. Newer
techniques such as diffusion tensor imaging may be of
greater help in the differential diagnosis of degenerative
dementias. DTI has demonstrated abnormal white mat-
ter in the parietal lobes of patients with DLB compared
to AD [29].
Functional studies may be more sensitive in detecting
abnormalities that differentiate various forms of demen-
tia. Thus fMRI studies reveal reduced frontal but
increased cerebellar activation during performance of a
working memory task in FTD compared to AD [30]. In
recent years, there has been increasing interest in net-
works of connectivity that are present during rest. Activ-
ity in the so-called default mode network, which
includes precuneus, posterior cingulate cortex, orbito-
frontal, medial prefrontal and ventral anterior cingulate
cortex, as well as inferior parietal, left dorsolateral pre-
frontal and left parahippocampal gyrus, is suppressed
during performance of a cognitive task [31]. Resting
state or task-free fMRI identifies networks whose activ-
ity is correlated over time. Default mode network activ-
ity is reduced in AD compared to controls [32]. In
contrast, behavioural variant FTD is associated with
increased activity in the default mode network but
reduced activity in the so-called salience network, which
encompasses fronto-insular, cingulate, striatal, thalamic
and brainstem nodes [33]. A detailed discussion of func-
tional network disruption in degenerative dementias has
recently appeared [34].
[18F]fluorodeoxyglucose (FDG) PET shows reduced
glucose metabolism in parietotemporal cortex in AD.
FDG PET has a small positive influence on sensitivity
and a modest influence on specificity compared with
initial clinical evaluation in AD. Positive and negative
predictive values for FDG PET compared to the gold
standard of pathological diagnosis are both approxi-
mately 0.8 and PET significantly enhances the diagnostic
accuracy of clinical evaluation [35]. Dementia with Lewy
bodies results in a greater degree of occipital hypometa-
bolism than AD and FDG PET may thus assist in the
differentiation of the two disorders, as verified at
autopsy [36]. Similarly, FDG PET may help improve
diagnostic accuracy for FTD versus AD, as the former
typically affects frontal lobes, anterior temporal and
anterior cingulate cortex [37]. Dementia with Lewy
bodies can also be differentiated from AD based on
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imaging evidence of dopamine deficiency using dopa-
mine transporter SPECT [38] or [18F]F-dopa PET [39].
While patterns of glucose hypometabolism may be
helpful in distinguishing between AD and control state,
as well as between AD and other dementing disorders,
in recent years interest has focused on the use of agents
that label amyloid. The best known of these is [11C]
labeled Pittsburgh Compound B (PiB), a thioflavin deri-
vative that appears to be specific for b-amyloid deposi-
tion [40]. A number of other [18F]-labeled agents have
been developed and these may prove useful, particularly
for centres at some distance from a cyclotron, given the
longer of half-life of [18F] (approximately 2 hours) com-
pared with that of [11C] (approximately 20 minutes). PiB
binding is increased in widespread cortical and subcorti-
cal regions in AD. This may clearly be helpful for the
differentiation of AD from frontotemporal dementia,
although a sizeable minority of FTD patients demon-
strate increased PiB uptake and it is not clear whether
this may represent concurrent AD pathology [41]. PiB
binding may also be present in patients with DLB or
PD-dementia, but this appears to reflect binding to b-
amyloid rather than to a-synuclein [42-44].
Early detection of preclinical disease
Parkinson’s disease
[18F]F-dopa PET shows evidence of asymptomatic dopa-
mine dysfunction in subjects exposed to the nigral neu-
rotoxin N-methyl-4-phenyl-1,2,3,6-tetrhydropyridine
(MPTP)[45] and in unaffected twins of subjects with
PD, particularly monozygotic [46]. In monozygotic
twins, the rate of decline in dopamine function is
greater than normal, and some of these individuals will
go on to develop symptomatic disease [46]. Progressive
decline of F-dopa uptake is also seen in individuals
exposed to MPTP, associated with emergence of new
clinical signs [47].
Radiotracer imaging shows evidence of abnormal
dopaminergic function in asymptomatic individuals
from families with known dominantly inherited PD,
such as PD due to mutations in LRRK2[48]. Using stan-
dard PET measures, reductions in dopamine transporter
(DAT) binding appear early, sometimes many years
prior to the expected age of onset, whereas the emer-
gence of clinical signs is associated with reduced F-dopa
uptake [49]. However, by using longer scan times with
F-dopa, one can determine effective dopamine turnover
and this appears to be the earliest indicator of abnorm-
alities in LRRK2 mutation carriers [50]. Whether abnor-
mal dopamine turnover is simply the earliest measurable
reflection of dopamine dysfunction in those destined to
develop disease or whether it is directly related to
mutated LRRK2 function in the absence of neuronal
dysfunction is as yet unclear.
Abnormal dopamine function has also been detected
in asymptomatic heterozygous carriers of recessively
inherited mutations for PD [51,52]. The significance of
this is unclear and scan abnormalities in such indivi-
duals progress much more slowly than is the case for
idiopathic PD, with no evidence of clinical manifesta-
tions over 5 years of follow up [53]. However, asympto-
matic heterozygous single mutation carriers for both
Parkin and PINK1 have morphometric abnormalities
(increased basal ganglia grey matter volume)[54] as well
as evidence for motor reorganization when performing a
task of internally selected finger movements [55,56].
Hyposmia is a common feature of PD and may be
present for some years prior to the manifestation of
motor abnormalities. A number of studies have demon-
strated abnormalities of DAT binding in hyposmic 1st
degree relatives of patients with PD, some of whom
then go on to develop PD at follow up [57]. Transcra-
nial sonography reveals increased echogenicity in the
substantia nigra of patients with PD, thought to reflect
increased iron deposition [58]. Hyposmic individuals
who also display abnormal nigral echogenicity have a
high likelihood of demonstrating abnormal reductions in
DAT binding [59].
REM sleep behaviour disorder (RBD) is associated
with the future development of neurodegenerative dis-
ease, mostly PD, in more than 50% of subjects over a
period of 12 years [60]. Patients with isolated RBD may
demonstrate reduced striatal dopamine function as
assessed by DTBZ PET [61]. A recent longitudinal study
using SPECT found reduced DAT binding at baseline in
50% of subjects, a more rapid rate of decline in DAT
binding in RBD subjects compared to controls, and the
emergence of PD in 3/20 RBD patients (those with the
lowest DAT binding) over the follow-up period of 3
years [62]. RBD has also been associated with abnormal
nigral echogenicity [63] and there are recent reports of
abnormal fractional anisotropy in the midbrain and pon-
tine tegmentum [64] as well as microstructural changes
in the white matter of the substantia nigra [65] of RBD
subjects.
Dementia
In the last decade, there has been growing interest in
the use of imaging to determine which subjects with
mild cognitive impairment (MCI) may go on to develop
AD. Measures of entorhinal cortex, superior temporal
sulcus and anterior cingulate cortex were able to discri-
minate approximately 75% of those subjects with
restricted memory impairment from those who con-
verted to AD within 3 years in one study [66]. Volume
based morphometry confirms the presence of early atro-
phy in medial temporal structures including amygdala,
anterior hippocampus, entorhinal cortex and fusiform
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gyrus in amnestic MCI subjects who progress to AD
[67], but those who convert from MCI to AD also show
signs of atrophy outside the medial temporal lobes, par-
ticularly lateral temporal and parietal cortex [68]. The
Alzheimer Disease Neuroimaging Initiative follows a
large cohort of subjects with multimodal imaging. Grey
matter density is reduced in amygdala, hippocampus
and insula as well as frontal and temporal cortex of
MCI converters compared to MCI with stable cognitive
function. Cortical thickness in lateral temporal cortex,
inferior parietal gyrus and precuneus also differentiates
between the two groups [69].
Diffusion tensor imaging may prove more sensitive
than traditional structural MRI measures. A recent
study found that amnestic MCI converters had changes
similar to those seen in established AD, whereas sub-
jects who did not convert had patterns similar to healthy
controls. The two amnestic MCI groups (converters vs.
non-converters) were distinguished by mean diffusivity
in total grey and white matter, hippocampus, insula,
frontal and parietal white matter, occipital grey and
white matter, as well as fractional anisotropy of tem-
poral white matter [70].
Early stages of disease may be associated with adaptive
changes in an attempt to compensate for the functional
deficit. It is therefore of interest that MCI may be asso-
ciated with increased hippocampal blood flow during
performance of a face-name encoding task, although the
response is decreased in patients with established AD
[71]. Mild cognitive impairment is associated with glu-
cose hypometabolism out of proportion to the degree of
atrophy in entorhinal cortex [72]. Entorhinal cortex
hypometabolism also predicts cognitive decline in
healthy subjects, particularly those who carry the ApoE4
genotype [73,74]. Progression of MCI to AD is predicted
by a combination of impaired episodic memory and glu-
cose hypometabolism [75], or by combining multiple
biomarkers in the form of anatomical MRI, FDG PET
and CSF measures of tau:Ab[76]. Somewhat more than
50% of MCI patients have evidence of abnormal amyloid
deposition on PET [77,78] and this appears to be asso-
ciated with an increased risk of conversion to AD
[79-81].
Concluding comments
The differential diagnosis of neurodegenerative disorders
is largely based on careful clinical assessment, but ima-
ging techniques may provide useful adjunctive informa-
tion. In the case of PD, radiotracer imaging can identify
those who have abnormal dopaminergic function, but
relatively specialized approaches are required to differ-
entiate the various conditions that may result in parkin-
sonism. Standard structural MRI is of relatively limited
utility in PD, but newer techniques that assess
connectivity and microstructural damage may play a
role. In the dementias, volumetric analysis of regional
tissue loss may be useful for differential diagnosis, but
the specificity is likely to be enhanced when combined
with fMRI or FDG PET measures of cerebral activation
and connectivity, as well as diffusion tensor measures of
anatomical connectivity. In the case of AD, specific ima-
ging markers of abnormal protein deposition are avail-
able, but this is not yet the case for the other
degenerative dementias or for the parkinsonian condi-
tions. The use of multimodal imaging, especially when
combined with other biomarkers, shows increasing pro-
mise for the detection of preclinical disease in indivi-
duals at increased risk and this may be of enormous
utility as better neuroprotective strategies are developed.
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